Literature DB >> 17075284

Recent advances in the development of anti-allergic drugs.

Hiroichi Nagai1, Hitomi Teramachi, Teruo Tuchiya.   

Abstract

Research over the past decade has provided information concerning the onset and treatment of allergic diseases, including bronchial asthma, allergic rhinitis and atopic dermatitis. Recent studies also indicated that allergic inflammation is the basic pathophysiology of allergic diseases and is closely associated with their progression and exacerbation. Our understanding of the mechanism of allergic inflammation with regard to therapeutic agents has improved as a result of immunological and molecular biological studies. While much effort has been paid to developing a new anti-allergic drug, allergic disease has yet to be completely conquered. More extensive research will allow the development of new therapeutics to combat allergic diseases. This article provides an overview of recent advances in the development of anti-allergic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075284     DOI: 10.2332/allergolint.55.35

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  10 in total

Review 1.  Strategies of mucosal immunotherapy for allergic diseases.

Authors:  Yi-Ling Ye; Ya-Hui Chuang; Bor-Luen Chiang
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

2.  Effectiveness of quercetin in an experimental rat model of allergic rhinitis.

Authors:  Mustafa Sagit; Halil Polat; Seren Gulsen Gurgen; Elife Berk; Sabri Guler; Mehmet Yasar
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-10       Impact factor: 2.503

3.  Allergen-induced airway inflammation and its therapeutic intervention.

Authors:  Paul M O'Byrne
Journal:  Allergy Asthma Immunol Res       Date:  2009-09-25       Impact factor: 5.764

4.  Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis.

Authors:  Erol Senturk; Yavuz Selim Yildirim; Remzi Dogan; Orhan Ozturan; Eray Metin Guler; Mehmet Serif Aydin; Abdurrahim Kocyigit; Mukaddes Esrefoglu; Ilker Kocak
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-10-25       Impact factor: 2.503

5.  The effect of inhaled inactived Mycobacterium phlei as a treatment for asthma.

Authors:  Moyu Ming; Chaoqian Li; Zhixi Luo; Shengqiu Lv; Qixiang Sun
Journal:  Mol Med Rep       Date:  2016-12-29       Impact factor: 2.952

6.  Pear pomace alleviated atopic dermatitis in NC/Nga mice and inhibited LPS-induced inflammation in RAW 264.7 macrophages.

Authors:  Mikyoung You; Ziyun Wang; Hwa-Jin Kim; Young-Hyun Lee; Hyeon-A Kim
Journal:  Nutr Res Pract       Date:  2022-01-10       Impact factor: 1.992

Review 7.  Respiratory allergies: a general overview of remedies, delivery systems, and the need to progress.

Authors:  Giuliano Molinari; Giselda Colombo; Cinzia Celenza
Journal:  ISRN Allergy       Date:  2014-03-12

8.  Antiatopic Dermatitis Effect of Artemisia iwayomogi in Dust Mice Extract-Sensitized Nc/Nga Mice.

Authors:  Hyekyung Ha; Hoyoung Lee; Chang-Seob Seo; Hye-Sun Lim; Mee-Young Lee; Jun Kyoung Lee; Hyeunkyoo Shin
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-23       Impact factor: 2.629

9.  Artemisia capillaris inhibits atopic dermatitis-like skin lesions in Dermatophagoides farinae-sensitized Nc/Nga mice.

Authors:  Hyekyung Ha; Hoyoung Lee; Chang Seob Seo; Hye-Sun Lim; Jun Kyoung Lee; Mee-Young Lee; Hyeunkyoo Shin
Journal:  BMC Complement Altern Med       Date:  2014-03-14       Impact factor: 3.659

10.  Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.

Authors:  Zahra Molavi; Sara Razi; Seyed Amir Mirmotalebisohi; Amirjafar Adibi; Marzieh Sameni; Farshid Karami; Vahid Niazi; Zahra Niknam; Morteza Aliashrafi; Mohammad Taheri; Soudeh Ghafouri-Fard; Shabnam Jeibouei; Soodeh Mahdian; Hakimeh Zali; Mohammad Mehdi Ranjbar; Mohsen Yazdani
Journal:  Biomed Pharmacother       Date:  2021-03-31       Impact factor: 6.529

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.